NOVO NORDISK B(0QIU.UK)

245.95+0.000.00%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
暂无新闻
公司概况
公司名称
NOVO NORDISK B
所属市场
LSE
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.novonordisk.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。

分时
5日
日
周
月

数据加载中...

最高

245.95

今开

245.95

量比

0.00

最低

245.95

昨收

245.95

换手率

0.00%

热议股票

{"pagemeta":{"title":"NOVO NORDISK B(0QIU.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NOVO NORDISK B(0QIU.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NOVO NORDISK B,0QIU.UK,NOVO NORDISK B股票,NOVO NORDISK B股票老虎,NOVO NORDISK B股票老虎国际,NOVO NORDISK B行情,NOVO NORDISK B股票行情,NOVO NORDISK B股价,NOVO NORDISK B股市,NOVO NORDISK B股票价格,NOVO NORDISK B股票交易,NOVO NORDISK B股票购买,NOVO NORDISK B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NOVO NORDISK B(0QIU.UK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NOVO NORDISK B(0QIU.UK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"news","symbol":"0QIU.UK","data":{"stockData":{"symbol":"0QIU.UK","market":"UK","secType":"STK","nameCN":"NOVO NORDISK B","latestPrice":245.95,"timestamp":1777044600000,"preClose":245.95,"halted":0,"volume":0,"delay":15,"changeRate":0,"nameEN":"NOVO NORDISK B","floatShares":3187922885,"shares":4443430040,"eps":23.03,"marketStatus":"已收盘","change":0,"latestTime":"04-24 16:30:00 BST 延时","open":245.95,"high":245.95,"low":245.95,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":23.03,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777273200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"LSE","adjPreClose":245.95,"openAndCloseTimeList":[[1777014000000,1777044600000]],"volumeRatio":0,"tradeCurrency":"DKK","tradeService":"EQS","exchangeMarketSize":500},"tweetData":null,"newsData":{"listData":[],"currentPage":1,"bottom":true},"noticeData":{"listData":[],"currentPage":1,"bottom":true},"companyData":{"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":0.0254},{"period":"1month","weight":0.0254},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.0254},{"period":"1year","weight":0.0254},{"period":"ytd","weight":0.0254}],"compareEarnings":[{"period":"1week","weight":-0.0119},{"period":"1month","weight":0.0538},{"period":"3month","weight":0.0434},{"period":"6month","weight":0.1023},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0665}],"compareStock":{"symbol":"ISF.UK","name":"FTSE100 ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.482759,"avgChangeRate":-0.00798},{"month":2,"riseRate":0.482759,"avgChangeRate":0.727563},{"month":3,"riseRate":0.241379,"avgChangeRate":0.002594},{"month":4,"riseRate":0.5,"avgChangeRate":0.020859},{"month":5,"riseRate":0.4,"avgChangeRate":0.006568},{"month":6,"riseRate":0.3,"avgChangeRate":0.002281},{"month":7,"riseRate":0.413793,"avgChangeRate":0.022857},{"month":8,"riseRate":0.344828,"avgChangeRate":0.001293},{"month":9,"riseRate":0.366667,"avgChangeRate":0.008458},{"month":10,"riseRate":0.451613,"avgChangeRate":-0.017241},{"month":11,"riseRate":0.551724,"avgChangeRate":0.018651},{"month":12,"riseRate":0.533333,"avgChangeRate":0.009089}],"exchange":"LSE","name":"NOVO NORDISK B","nameEN":"NOVO NORDISK B"},"aProfile":null}}}